Abingdon Health Plc (ABDXF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Abingdon Health Plc (ABDXF) with AI Score 54/100 (Hold). Abingdon Health Plc develops, manufactures, and distributes diagnostic devices globally, including rapid antibody and antigen tests. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Abingdon Health Plc (ABDXF) Healthcare & Pipeline Overview
Abingdon Health Plc specializes in diagnostic device development, manufacturing, and distribution, focusing on rapid testing solutions like COVID-19 tests and nucleic acid lateral flow immunoassays. The company serves a global market, offering both product sales and contract services within the medical diagnostics industry.
Investment Thesis
Abingdon Health Plc presents a focused play on the diagnostics market, particularly in rapid testing solutions. With a market capitalization of $0.01 billion, the company's negative P/E ratio of -9.12 reflects current challenges in achieving profitability, despite a gross margin of 37.1%. Key value drivers include expansion of its contract manufacturing services and successful commercialization of its AppDx technology. Growth catalysts include potential partnerships and increased demand for rapid diagnostic solutions. Potential risks include competition from established players and the need to achieve sustainable profitability. Investors should monitor the company's ability to leverage its existing product portfolio and strategic collaborations to drive revenue growth and improve financial performance.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion indicates a small-cap company with potential for growth but also higher risk.
- Negative P/E ratio of -9.12 reflects current unprofitability, requiring careful monitoring of future earnings.
- Gross margin of 37.1% demonstrates the potential for profitability if operational efficiencies are improved.
- Beta of 0.18 suggests low volatility compared to the overall market, indicating a relatively stable stock.
- Collaboration with Abcam plc provides access to a broader market and enhances product development capabilities.
Competitors & Peers
Strengths
- Established expertise in lateral flow technology.
- Manufacturing capabilities for diagnostic devices.
- Collaboration with Abcam plc.
- Diverse product portfolio including COVID-19 tests.
Weaknesses
- Negative P/E ratio indicating current unprofitability.
- Small market capitalization.
- Dependence on COVID-19 testing market.
- Limited brand recognition compared to larger competitors.
Catalysts
- Upcoming: Potential new contract manufacturing agreements.
- Ongoing: Commercialization of AppDx technology.
- Ongoing: Expansion of diagnostic test portfolio.
- Ongoing: Strategic partnerships and collaborations.
- Ongoing: Geographic expansion into new markets.
Risks
- Potential: Intense competition from established diagnostic companies.
- Potential: Decline in demand for COVID-19 testing.
- Potential: Regulatory changes in the healthcare industry.
- Potential: Economic downturn affecting healthcare spending.
- Ongoing: Negative P/E ratio indicating current unprofitability.
Growth Opportunities
- Expansion of Contract Manufacturing Services: Abingdon Health can leverage its manufacturing capabilities to secure more contract manufacturing agreements with other healthcare companies. The global contract manufacturing market for medical devices is projected to reach $108.1 billion by 2027, presenting a significant opportunity for Abingdon Health to increase its revenue and profitability. Timeline: Ongoing.
- Commercialization of AppDx Technology: The AppDx technology, which transforms smartphones into lateral-flow readers, has the potential to disrupt the point-of-care diagnostics market. By partnering with healthcare providers and diagnostic test developers, Abingdon Health can drive adoption of AppDx and generate recurring revenue through software licenses and data analytics services. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Abingdon Health can pursue strategic partnerships and collaborations with other companies in the healthcare industry to expand its product portfolio and market reach. The collaboration with Abcam plc is a positive example, and further partnerships could accelerate growth. Timeline: Ongoing.
- Development of New Diagnostic Tests: Abingdon Health can invest in the development of new diagnostic tests for various diseases and conditions. The global diagnostics market is expected to reach $137.7 billion by 2028, driven by advancements in technology and increasing demand for personalized medicine. Timeline: Ongoing.
- Geographic Expansion: Abingdon Health can expand its operations into new geographic markets, particularly in developing countries where there is a growing need for affordable and accessible diagnostic tests. The company can leverage its existing product portfolio and manufacturing capabilities to establish a presence in these markets. Timeline: Ongoing.
Opportunities
- Expansion of contract manufacturing services.
- Commercialization of AppDx technology.
- Development of new diagnostic tests.
- Geographic expansion into developing markets.
Threats
- Intense competition from established diagnostic companies.
- Decline in demand for COVID-19 testing.
- Regulatory changes in the healthcare industry.
- Economic downturn affecting healthcare spending.
Competitive Advantages
- Proprietary lateral flow technology.
- Established manufacturing capabilities.
- Strategic collaboration with Abcam plc.
- Expertise in diagnostic test development.
About ABDXF
Abingdon Health Plc, incorporated in 2008 and headquartered in York, United Kingdom, operates within the medical diagnostics industry, focusing on the development, manufacture, and distribution of a range of diagnostic devices. The company's product portfolio includes the AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test, as well as nucleic acid lateral flow immunoassays, PCRD and PCRD FLEX for rapid readouts post isothermal amplification, the Abingdon Simply Test range of self-tests, and the 2019-nCoV Antigen Test for qualitative detection of antigens to SARS-CoV-2. Abingdon Health also offers AppDx, a customizable image capturing technology that transforms smartphones into lateral-flow readers. Beyond its proprietary products, Abingdon Health provides contract manufacturing, nucleic acid lateral flow test customization, and lateral flow development and manufacturing services. The company extends its expertise through consultancy services to businesses operating in the healthcare technology sector. Abingdon Health has a collaboration and co-marketing agreement with Abcam plc, enhancing its market reach and product development capabilities.
What They Do
- Develops rapid diagnostic tests for infectious diseases.
- Manufactures lateral flow immunoassays.
- Offers COVID-19 antibody and antigen tests.
- Provides contract manufacturing services for diagnostic devices.
- Offers a smartphone-based lateral flow reader technology (AppDx).
- Provides consultancy services to healthcare technology businesses.
Business Model
- Sales of rapid diagnostic tests (e.g., COVID-19 tests).
- Contract manufacturing for other diagnostic companies.
- Licensing and sales of AppDx technology.
- Consultancy services for healthcare businesses.
Industry Context
Abingdon Health Plc operates in the medical diagnostics industry, a sector characterized by continuous innovation and increasing demand for rapid and accurate testing solutions. The market is driven by factors such as the growing prevalence of infectious diseases, the increasing adoption of point-of-care diagnostics, and advancements in biotechnology. Competitors include companies like CRPOF (CareRx Corporation), EIGRQ (Eurofins Scientific SE), MNNDF (MIND Technology, Inc.), NOXOF (Noxopharm Ltd), and PXXLF (Pro-Dex, Inc.). Abingdon Health's focus on lateral flow technology positions it to capitalize on the demand for rapid and cost-effective diagnostic tests.
Key Customers
- Healthcare providers (hospitals, clinics).
- Diagnostic test developers.
- Pharmaceutical companies.
- Research institutions.
Financials
Chart & Info
Abingdon Health Plc (ABDXF) stock price: Price data unavailable
Latest News
No recent news available for ABDXF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ABDXF.
Price Targets
Wall Street price target analysis for ABDXF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ABDXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christopher William Hand
CEO
Christopher William Hand serves as the CEO of Abingdon Health Plc, managing a team of 113 employees. His background includes extensive experience in the healthcare and diagnostics industries. Prior to joining Abingdon Health, he held leadership positions at various companies, focusing on commercial strategy, product development, and market expansion. He brings a wealth of knowledge in driving growth and innovation within the healthcare sector.
Track Record: Under Christopher William Hand's leadership, Abingdon Health has focused on expanding its product portfolio and strengthening its manufacturing capabilities. Key achievements include securing strategic collaborations and launching new diagnostic tests. He has overseen the development and commercialization of the AppDx technology, as well as navigated the company through the challenges and opportunities presented by the COVID-19 pandemic.
ABDXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Abingdon Health Plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price volatility.
- Lack of regulatory oversight.
- Higher risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's OTC Markets profile and disclosure status.
- Check for any regulatory actions or legal proceedings against the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Established manufacturing capabilities.
- Collaboration with Abcam plc.
- Development of proprietary technology (AppDx).
- Operating history since 2008.
- CEO with experience in the healthcare industry.
Abingdon Health Plc Stock: Key Questions Answered
What does Abingdon Health Plc do?
Abingdon Health Plc is a medical diagnostics company that develops, manufactures, and distributes a range of diagnostic devices, including rapid antibody and antigen tests for infectious diseases like COVID-19. The company also offers contract manufacturing services for other diagnostic companies and has developed AppDx, a smartphone-based lateral flow reader technology. Abingdon Health serves healthcare providers, diagnostic test developers, and pharmaceutical companies worldwide.
What do analysts say about ABDXF stock?
AI analysis is currently pending for ABDXF. However, given the company's small market capitalization and negative P/E ratio, analysts are likely to focus on its ability to achieve profitability and generate sustainable revenue growth. Key valuation metrics to consider include revenue growth rate, gross margin, and operating expenses. Investors should monitor the company's progress in commercializing its AppDx technology and securing new contract manufacturing agreements.
What are the main risks for ABDXF?
The main risks for Abingdon Health Plc include intense competition from larger and more established diagnostic companies, a potential decline in demand for COVID-19 testing, and regulatory changes in the healthcare industry. The company's negative P/E ratio also indicates a risk of continued unprofitability. Additionally, as an OTC-listed stock, ABDXF is subject to higher liquidity risk and potential price volatility compared to stocks listed on major exchanges.
What are the key factors to evaluate for ABDXF?
Abingdon Health Plc (ABDXF) currently holds an AI score of 54/100, indicating moderate score. Key strength: Established expertise in lateral flow technology.. Primary risk to monitor: Potential: Intense competition from established diagnostic companies.. This is not financial advice.
How frequently does ABDXF data refresh on this page?
ABDXF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ABDXF's recent stock price performance?
Recent price movement in Abingdon Health Plc (ABDXF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established expertise in lateral flow technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ABDXF overvalued or undervalued right now?
Determining whether Abingdon Health Plc (ABDXF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ABDXF?
Before investing in Abingdon Health Plc (ABDXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may be limited or delayed.
- AI analysis pending for ABDXF.